IL6 and peripheral arterial disease: Studies such as those by Signorelli et al. (2016) and Takamura et al. (2017) demonstrated significant elevations in IL-6 levels in PAD patients and post-endovascular therapy, respectively, indicating that IL-6 is a key marker of inflammation in these conditions.